A Phase 1b, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Imvotamab in Adult Participants With Active, Refractory Moderate-Severe Idiopathic Inflammatory Myopathies

The purpose of this study is to determine the safety and tolerability of imvotamab in patients with Moderate-Severe Idiopathic Inflammatory Myopathies who have failed prior therapies.
Participants will be given imvotamab through a vein (i.e., intravenously).

开始日期2024-07-01

申办/合作机构

IGM Biosciences, Inc.

CTIS2023-506499-29-00 / Recruiting

- IGM-2323-101

开始日期2024-06-03

申办/合作机构

IGM Biosciences, Inc.

CTIS2023-505127-31-00 / Not yet recruiting

- IGM-2323-102

开始日期2024-05-06

申办/合作机构

IGM Biosciences, Inc.

100 项与 Imvotamab 相关的临床结果

登录后查看更多信息

100 项与 Imvotamab 相关的转化医学

登录后查看更多信息

100 项与 Imvotamab 相关的专利（医药）

登录后查看更多信息

项与 Imvotamab 相关的文献（医药）

2023-09-01·Targeted oncology

Population Pharmacokinetics and Exposure-Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1.

Article

作者: Wu, Liviawati S ; Kobos, Rachel ; Girgis, Suzette ; Zhou, Honghui ; Hickey, Kathleen ; Pei, Lixia ; Apte, Amit ; Trancucci, Danielle ; Uhlar, Clarissa M ; Banerjee, Arnob ; Kemmerer, Kristy ; Samtani, Mahesh N ; Su, Yaming ; Garfall, Alfred L ; Verona, Raluca ; Stephenson, Tara ; Iwaki, Yuki ; Ouellet, Daniele ; Xu, Yan ; Chen, Yang ; Miao, Xin ; Krishnan, Amrita ; Goldberg, Jenna D ; Guo, Yue ; Lin, Shun Xin Wang ; Desai, Rachit ; Usmani, Saad Z

BACKGROUND:

Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, is approved in patients with relapsed/refractory multiple myeloma (RRMM) who have previously received an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody.

OBJECTIVE:

We report the population pharmacokinetics of teclistamab administered intravenously and subcutaneously (SC) and exposure-response relationships from the phase I/II, first-in-human, open-label, multicenter MajesTEC-1 study.

METHODS:

Phase I of MajesTEC-1 consisted of dose escalation and expansion at the recommended phase II dose (RP2D; 1.5 mg/kg SC weekly, preceded by step-up doses of 0.06 and 0.3 mg/kg); phase II investigated the efficacy of teclistamab RP2D in patients with RRMM. Population pharmacokinetics and the impact of covariates on teclistamab systemic exposure were assessed using a 2-compartment model with first-order absorption for SC and parallel time-independent and time-dependent elimination pathways. Exposure-response analyses were conducted, including overall response rate (ORR), duration of response (DoR), progression-free survival (PFS), overall survival (OS), and the incidence of grade ≥ 3 anemia, neutropenia, lymphopenia, leukopenia, thrombocytopenia, and infection.

RESULTS:

In total, 4840 measurable serum concentration samples from 338 pharmacokinetics-evaluable patients who received teclistamab were analyzed. The typical population value of time-independent and time-dependent clearance were 0.449 L/day and 0.547 L/day, respectively. The time-dependent clearance decreased rapidly to < 10% after 8 weeks of teclistamab treatment. Patients who discontinue teclistamab after the 13th dose are expected to have a 50% reduction from C_max in teclistamab concentration at a median (5th to 95th percentile) time of 15 days (7-33 days) after T_max and a 97% reduction from C_max in teclistamab concentration at a median time of 69 days (32-163 days) after T_max. Body weight, multiple myeloma type (immunoglobulin G vs non-immunoglobulin G), and International Staging System (ISS) stage (II vs I and III vs I) were statistically significant covariates on teclistamab pharmacokinetics; however, these covariates had no clinically relevant effect on the efficacy of teclistamab at the RP2D. Across all doses, ORR approached a plateau at the concentration range associated with RP2D, and in patients who received the RP2D, a flat exposure-response curve was observed. No apparent relationship was observed between DoR, PFS, OS, and the incidence of grade ≥3 adverse events across the predicted exposure quartiles.

CONCLUSION:

Body weight, myeloma type, and ISS stage impacted systemic teclistamab exposure without any clinically relevant effect on efficacy. The exposure-response analyses for ORR showed a positive trend with increasing teclistamab systemic exposure, with a plateau at the RP2D, and there was no apparent exposure-response trend for safety or other efficacy endpoints. These analyses support the RP2D of teclistamab in patients with RRMM.

CLINICAL TRIAL REGISTRATION:

NCT03145181 (phase I, 09 May 2017); NCT04557098 (phase II, 21 September 2020).

1995-10-01·Journal of hematotherapy

Clinical Experience with CD3 X CD19 Bispecific Antibodies in Patients with B Cell Malignancies

Article

作者: Phillips, J ; Clark, M ; Van Dijk, A ; De Weger, R A ; De Gast, G C ; Bast, B J ; Haagen, I A ; Van Houten, A A ; Klein, S

In extensive preclinical testing, a CD3 x CD19 bispecific antibody (BsAb) induced killing of malignant B cells by resting T cells even in an autologous situation. In a 14 day clonogenic assay using a CD19+ pre-B cell line (REH), BsAb required repeated administration together with IL-2 to achieve a 5 log kill by resting peripheral blood T cells. Intravenously administered BsAb in an intrapatient dose escalation study of 3 patients with B cell non-Hodgkin's lymphoma showed limited toxicity (WHO grade II fever and chills) due to tumor necrosis factor-alpha (TNF-alpha) release by T cells. Pharmacokinetics with 2.5 mg BsAb showed peak levels of 200-300 micrograms/ml and a t1/2 of 10.5 h. The next patient, with chronic lymphocytic leukemia (CLL), received 0.6 mg BsAb/m2 as an i.v. infusion preceded by 1 MU IL-2/m2 s.c. Improved T cell activation was noted, as indicated by an increase in IFN-gamma, IL-6, IL-8, and IL-10, in addition to high TNF-alpha increases. TNF-alpha increases were highest on the first day. Toxicity remained restricted to grade II fever and chills, observed every day after the infusion of BsAb. No clear clinical effects were seen in this chemotherapy-resistant CLL patient with a high tumor burden. If subsequent patients also show limited toxicity, treatment of patients with a lower tumor load seems to be warranted to evaluate the efficacy of CD3 x CD19 BsAb therapy.

1995-06-01·Blood1区 · 医学

The efficacy of CD3 x CD19 bispecific monoclonal antibody (BsAb) in a clonogenic assay: the effect of repeated addition of BsAb and interleukin-2

1区 · 医学

Article

作者: de Gast, BC ; de Lau, WB ; Bast, BJ ; Geerars, AJ ; Haagen, IA

To evaluate the potency by which human T cells are targeted and activated by bispecific monoclonal antibodies (BsAbs) to lyse tumor cells, a clonogenic assay was developed. The efficacy of a CD3 x CD19 BsAb binding to both the CD3 T-cell antigen and the CD19 B-cell antigen was already proven in 51Cr-release assays and in 3-day activation cultures. To achieve more quantitative results, a 14-day clonogenic assay, based on limiting-dilution, was performed for the determination of the initial and residual number of clonogenic units obtained with a CD19+ pre-pre-B acute lymphoblastic leukemia (ALL-B) cell line. Elimination of up to 5 logs of ALL-B cells by freshly isolated peripheral blood mononuclear cells (PBMCs) cultured with BsAb plus interleukin-2 (IL-2) could be detected. The presence of human IgG did not abolish the effect. Repeated addition of each of the two agents was necessary, because a single treatment produced only a 1- to 2-log kill. CD3 monoclonal antibody and IL-2 stimulation (“lymphokine-activated killer cell” conditions) resulted in only a 2-log kill. The number of T cells proved critical in lysis of ALL-B cells, with a 5-log kill using a T-cell:B-cell ratio of 3:1 but with only a 1-log kill using a ratio of 1:1. PBMCs isolated from patients with non-Hodgkin's lymphoma, both in relapse or remission, proved to be as competent as those from healthy donors in removing ALL-B cells. This clonogenic assay shows the importance of repeated administration of CD3 x CD19 BsAb and IL-2 and offers the possibility to compare it with other therapies in B-cell malignancy.

项与 Imvotamab 相关的新闻（医药）

2024-10-31

·艾美达医药咨询

国产新药爆红

无心插柳柳成荫。 TCE双抗出海在近期迎来“爆红”，被MNC买家们重点青睐和押注的方向，不是过去研发者们重点突破的肿瘤方向，而是在自免领域。今年8月以来，国内Biotech分别完成了有关于四项与自免方向有关的TCE双抗BD交易，包括嘉和生物（CD3/CD20双抗）、岸迈生物（BCMA/CD3双抗）的Newco交易，还有就是同润生物和默沙东达成CD3/CD19双抗的巨额交易，以及GSK收购恩沐生物的CD3/CD19/CD20三抗CMG1A46的最新合作。其中诞生了在国内Biotech出海史上两项价值巨大的交易，同润生物和默沙东的合作首付款为7亿美金，仅次于BMS与百利天恒关于双抗ADC的合作；而GSK与恩沐生物的交易首付款为3亿美元，在过去国内众多BD交易中可算是第一梯队的水准。在“美元攻势”指明MNC喜好之下，我想下一个国产创新药赔率最高的出海机会呼之欲出。 01 “CD3+B细胞靶标”多抗，在自免的机制与潜力自免疾病可分为两种类型，一种是T细胞介导的免疫反应，其特征是免疫反应过度并攻击自身组织；另一种是B细胞介导的免疫反应，B细胞会产生自身抗体来介导免疫反应。而B细胞介导的自免疾病，最典型的是弥漫性结缔组织病（包括类风湿关节炎、干燥综合征等），其次也有分散在不同学科的适应症（重症肌无力、多发性硬化、天疱疮和溶血性贫血等）。基于这类自免疾病发病基础是产生自身抗体的自身反应性B细胞，B细胞耗竭疗法（BCDT）应运而生，其通过一定手段来清除B细胞从而减弱自身免疫来达到治疗目的，已经在单抗、CAR-T分子层面展现出了巨大潜力。在BCDT策略上，如何选择B细胞清除药物靶标就显得比较关键。 B细胞在骨髓中发育，成熟后进入外周血，其依次明确的表面抗原和DNA重排情况可分为：祖B细胞、前B细胞、未成熟B细胞、过渡B细胞、初始B细胞、记忆细胞、原浆细胞和浆细胞等。其中，B细胞表面抗原包括CD19、CD20、CD38、CD138等，值得注意的是由于CD19在B细胞全生命周期表达、CD20在祖B细胞和浆细胞不表达，这两大靶点成为热门的研究目标。（图源：医药速览）从理论上来看，对比针对B细胞清除药物靶标的单抗来说，TCE双抗一端定位各种B细胞，另外一端连接T细胞的CD3表位，有望更深度、更持久的清除B细胞，达到持续治疗B细胞介导的自免疾病。目前，已经有成熟药物在早期临床中初步验证了CD3双抗对于自免疾病的疗效。 2024年4月Georg Schett在《Nature Medicine》期刊发表的论文显示，在6名严重多重耐药的类风湿性关节炎患者（RA）研究中，使用了非常低剂量的安进CD19/CD3双抗Blinatumomab对患者进行治疗，结果显示：Blinatumomab的治疗成功使得患者B细胞耗竭且伴随T细胞数量减少，患者临床疾病活动迅速下降且滑膜病变得到改善（B细胞和浆细胞大量存在于发炎的滑膜），并降低了自身抗体水平（自身抗体与RA患者严重疾病进展有关）；研究中安全性良好，未出现CRS（细胞因子风暴）。除了Blinatumomab之外，2024年9月新英格兰医学杂志（NEJM）刊登了两篇强生Teclistamab（CD3/BCMA双抗）治疗自身免疫疾病的文章，其中一项研究展示了Blinatumomab治疗使得一名拥有6年病史、多款药物经治未出现显著缓解的系统性红斑狼疮（SLE）患者实现了完全缓解；另一项研究，Teclistamab对4位5种以上免疫抑制剂耐药的自免患者进行治疗，包括系统性硬化症、原发性干燥综合征、特发性炎性肌病以及RA患者，所有患者均取得积极疗效。（图源：NEJM） TCE双抗在自免疾病展现出的潜力，对于近年因自免疾病再次热门起来的CAR-T和细胞治疗遭受较大竞争压力（目前美国已提交了35项SLE细胞疗法的IND，中国正在开发用于治疗自免疾病的CAR-T产品管线已有几十款）。相比CAR-T疗法患者治疗前需清淋、等待制造过程并进行回输后观察，TCE双抗作为非个性化的通用药物，且可以制作成皮下注射剂型，患者依从性更佳。 02 国内BD先锋分子的吸引力恩沐生物一个自免适应症都还没进入临床的三抗CMG1A46，为什么值得3亿美元的首付款？答案可能是基于CMG1A46定位于更新一代的TCE多抗，对于现有的TCE双抗有着潜在“降维打击”的能力，这从其在几年前在ASH大会上公布的临床前数据就可见一斑。据医药观澜报道的数据显示，CMG1A46针对非霍奇金淋巴瘤（DLBCL）临床前数据具备几个显著的特征： 1）高亲和力：CMG1A46与肿瘤细胞表面的CD19和CD20具有很高的亲和力（即便是CD20痕量表达的DLBCL），同理这意味着其对CD19、CD20表达的B细胞可能存在很强的耗竭能力； 2）疗效&安全性初探：相对传统的CD3/CD20，CMG1A46在临床前数据展出更强的肿瘤抑制活性；更值得注意的是，CMG1A46的剂量是传统CD3/CD20双抗的6倍，安全性风险却未有明显增加； 3）半衰期：据报道，高亲和力的CD3双抗往往会导致较短的血清半衰期，而CMG1A46在食蟹猴的药代动力学研究表明，1mpk给药时CMG1A46在血清中的半衰期超过70小时。（图：诺华类似的CD3/CD19/CD20三抗）另外，获得默沙东青睐、以7亿美元首付款授出全球权益的同润生物CD3/CD19双抗CN201同样值得关注。 CN201的发现基于药明生物的WuXibody双抗平台，据介绍，该平台特点在于几乎可利用所有抗体序列构建双抗，同时可灵活构建各种不同的价数的双抗，并可降低管线的免疫原性风险和延长在人体内半衰期。更值得注意的是，CN201在ASCO大会公布急性B淋巴细胞白血病一期临床数据显示：51位患者中有7位接受高剂量治疗，其中有6位完全应答（CR）；安全性方面，所有患者中只有2位患者出现3级CRS，并未出现4级CRS事件。据上述早期中型样本量临床看，相信默沙东花大价钱收购CN201很大程度基于其疗效和安全性的平衡，在具备强大的B细胞耗竭能力的同时保证长期治疗的安全性，这在大部分自免疾病中非常重要。 03 国内外潜力新星目前，全球范围内有超过20款TCE双抗开展了自免领域适应症探索，靶点选择集中在CD3/CD19、CD3/CD20、CD3/BCMA，大部分处于临床一期及临床前的阶段。（图源：禾开生物）海外研发进度靠前、以自免TCE多抗为核心管线的Biotech包括Cullinan Therapeutics、IGM Biosciences、Xencor等。 IGM Biosciences以构建多个CD3双抗的IgM平台而崭露头角，2年前与赛诺菲达成3个肿瘤学靶点和3个免疫学靶点的管线合作，后调整方向专注在自免领域。目前，公司进度最快的管线是CD20/CD3双抗Imvotamab，在SLE、RA等适应症上开展一期临床。尽管Imvotamab自免适应症临床数据尚未读出，但早期基于近100名非霍奇金淋巴瘤（NHL）患者的数据，imvotamab展现出良好的安全性（所有剂量组CRS发生率为15%），并在结合和杀死低CD20表达细胞方面显示出优越的效力。 Cullinan Therapeutics同样是海外市场备受关注的Biotech，其CD19/CD3双抗CLN-978早前刚刚进入临床阶段，成为首个FDA批准自免适应症IND的CD19 T细胞衔接器。CLN-978的设计具备一定的特点，其经工程改造可实现与CD19的极高亲和力结合（即便是CD19表达量极低的B细胞），另外其还含有一个与人血清白蛋白结合的单结构域抗体，以延长血清半衰期。在CLN-978过去已有的一期DLBCL临床中，3名患者每周接受30mg皮下注射，在首次给药后96小时内2名具有可检测基线B细胞的患者外周B细胞分别减少了93%和98%，而两名肿瘤体积较大的患者在首次给药后出现了一级CRS事件。不难看出，CLN-978具备强劲的B细胞耗竭潜力，同时安全性未来需要在SLE临床中进一步观察。神州细胞的SCTB35已经进入临床阶段，其为国内首款皮下注射CD20/CD3双抗，首个推进适应症为DLBCL，在今年9月国内获批了B细胞介导的自身免疫性疾病临床。其余国产TCE双抗均处于较早阶段，包括恒瑞医药、德琪医药、和铂医药、亿帆医药等均有布局。结语：以长效自免单抗为核心管线的Biotech在海外的估值正在水涨船高，而TCE双抗作为能够更深度、更持续清除B细胞的新一代疗法，在未来的自免治疗格局上显然有机会占有一席之地，而最终决定性的因素，便是看哪家MNC或者Biotech能够做出一个类达必妥的安全性、有效性兼顾的出色产品。本文转载自瞪羚社/Kris. 免责声明本文系转载，仅做分享之用，不代表平台观点。图片、文章、字体等版权均属于原作者所有，如有侵权请告知，我们会及时处理。 ------------------------------ 「长按」二维码添加小达「进群」与更多行业伙伴共探市场前沿资讯艾美达医药咨询艾美达（北京）医药信息咨询有限公司，成立于2014年4月，是一家专业的医药行业咨询服务提供商。公司致力于将产业政策研究与真实世界的数据挖掘深度结合，洞悉行业政策对市场的影响，通过专业的研究提供前瞻性的市场分析，为企业产品上市后的市场准入提供整体解决方案。

并购细胞疗法抗体药物偶联物免疫疗法

2024-10-01

·FierceBiotech

IGM completes pivot from cancer to autoimmune, shaking up C-suite and hinting at layoffs

Alongside IGM Biosciences' strategic shift, CEO Fred Schwarzer, Chief Scientific Officer Bruce Keyt, Ph.D., and Chief Medical Officer Chris Takimoto, M.D., Ph.D., are all leaving their roles. IGM Biosciences ended last year laying off staff and streamlining its cancer pipeline. Now, the company has become the latest to join a hot trend in cell therapy biotech—pivoting from oncology to autoimmune disease.The strategic shift—which comes with a side order of a C-suite shake-up and hints of further layoffs—shouldn’t be a huge surprise. Back in December 2023, IGM confirmed that while it was halting work on two candidates aimed at blood cancer and solid tumors, it was persevering in colorectal cancer and autoimmune diseases.Now, the company has announced a “strategic pivot to focus exclusively on autoimmunity disease.” In practice, it means that the biotech’s resources will be channeled toward its pipeline of T-cell engagers being lined up in autoimmunity conditions.These are led by imvotamab, a CD20 x CD3 bispecific T cell engager that is already being evaluated in clinical trials for rheumatoid arthritis, systemic lupus erythematosus and myositis. Those studies are due to start reading out this year and into next. Next in the queue is IGM-2644, a CD38 x CD3 bispecific set to begin a clinical trial for generalized myasthenia gravis before the end of 2024.The flip side of this refocus is that spending on the IgM antibody aplitabart as well as IGM’s other oncology R&D will be “minimized.” In a post-market release Sept. 30, the company alluded to “emerging data” from the ongoing trial of aplitabart in colorectal cancer as one of the reasons for the decision, along with the “significant opportunity in autoimmunity.”IGM’s workforce suffered a 22% reduction as part of the last round of pipeline changes in December, and it sounds like more layoffs could be in store for the biotech’s staff.“The company has decided to immediately begin taking steps, including a reduction in force, to minimize its future spending on the research and clinical development of aplitabart and other oncology candidates,” IGM explained in the release.The company had previously expected to end this year with $180 million in cash and investments, which should fund its operations into the second quarter of 2026. Yesterday’s pipeline changes mean IGM’s cash runway will now stretch into 2027, it said.Alongside the strategic shift, IGM is making some major changes to its C-suite, with CEO Fred Schwarzer, Chief Scientific Officer Bruce Keyt, Ph.D., and Chief Medical Officer Chris Takimoto, M.D., Ph.D., all leaving their roles—although Schwarzer and Keyt will remain as consultants. Mary Beth Harler, M.D., a Bristol Myers Squibb veteran who joined IGM in 2021 to head up the biotech's autoimmune R&D, will step into the CEO role.“Our early pivot to using T cell engagers in autoimmune disease has enabled significant progress on these programs at IGM, and I am excited to lead the company at this transformational stage,” Harler said in the release.“We’ve made great progress in our clinical development of imvotamab in autoimmune indications and we believe the clinical, and ultimately commercial, potential of our pipeline of T cell engaging antibodies in treating autoimmune diseases is significant,” the new CEO added.IGM is treading a well-worn path of oncology cell therapy companies taking an increased interest in the autoimmune space, including the likes of Poseida Therapeutics, Allogene and Caribou Biotherapeutics.

细胞疗法高管变更

2024-09-30

·EndPoints

IGM scraps oncology work to focus on autoimmune, loses three executives

IGM Biosciences will stop working in cancer and shrink its T cell engager pipeline to focus on autoimmune diseases, the California biotech said late Monday. The company’s CEO, Fred Schwarzer, is leaving the company as well, and will be replaced by Mary Beth Harler. Harler came to IGM in 2021 as president of its autoimmunity work after 11 years at Bristol Myers Squibb. CSO Bruce Keyt is also departing, and medical chief Chris Takimoto is leaving “to pursue an opportunity outside” IGM, the company said. “We believe the clinical, and ultimately commercial, potential of our pipeline of T cell engaging antibodies in treating autoimmune diseases is significant,” Harler said in a press release. The company said it plans to share initial clinical data from its drug imvotamab by the end of this year or early next year. IGM’s share price $IGMS was down more than 15% after Monday’s closing bell. The company said its cash runway now extends into 2027, up from a prior guidance of the second quarter of 2026. The program and leadership changes come a few months after Sanofi halved the duo’s multibillion-dollar pact , removing three oncology targets but keeping inflammation and immunology plans. Mountain View, CA-based IGM also scrapped a blood cancer program last year and laid off 22% of its workforce. IGM’s oncology work had included a Phase 1 colorectal cancer drug known as aplitabart. The trial completed enrollment and was on track for topline results before next April. Now, IGM will focus on the CD20xCD3 bispecific imvotamab, which is in Phase 1 testing for rheumatoid arthritis, systemic lupus erythematosus and myositis. The company also expects to enter the clinic by the end of this year with IGM-2644, a CD38xCD3 bispecific T cell engager for generalized myasthenia gravis. T cell engagers have started to make their way into autoimmune diseases. Merck is interested in the application of the modality in autoimmune diseases, paying $700 million upfront for an experimental treatment from Curon Biopharmaceutical . Ken Song’s Candid Therapeutics emerged last month with more than $370 million to advance two clinical-stage programs.

临床1期高管变更

100 项与 Imvotamab 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
弥漫性大B细胞淋巴瘤	临床2期	美国	IGM Biosciences, Inc.	2019-09-30
弥漫性大B细胞淋巴瘤	临床2期	澳大利亚	IGM Biosciences, Inc.	2019-09-30
弥漫性大B细胞淋巴瘤	临床2期	捷克	IGM Biosciences, Inc.	2019-09-30
弥漫性大B细胞淋巴瘤	临床2期	法国	IGM Biosciences, Inc.	2019-09-30
弥漫性大B细胞淋巴瘤	临床2期	意大利	IGM Biosciences, Inc.	2019-09-30
弥漫性大B细胞淋巴瘤	临床2期	韩国	IGM Biosciences, Inc.	2019-09-30
弥漫性大B细胞淋巴瘤	临床2期	西班牙	IGM Biosciences, Inc.	2019-09-30
滤泡性淋巴瘤	临床2期	美国	IGM Biosciences, Inc.	2019-09-30
滤泡性淋巴瘤	临床2期	澳大利亚	IGM Biosciences, Inc.	2019-09-30
滤泡性淋巴瘤	临床2期	捷克	IGM Biosciences, Inc.	2019-09-30

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04082936 (EHA2022)	临床1期	非霍奇金淋巴瘤	-	IGM-2323 100 mg	遞夢築艱獵廠積鹹積艱(齋廠憲窪醖遞構壓遞鬱) = limited 餘憲夢築鬱襯醖築製選 (衊憲艱齋艱夢顧積積夢 )	-	2022-05-12
NCT04082936 (ASH2021) 人工标引	临床1期	B细胞恶性肿瘤	29	IGM-2323	鹹鬱襯製鬱範艱蓋淵鹹(窪構遞範網窪鑰選鬱廠) = 3 pts (1 each Gr1/2/3) 顧廠鏇廠齋窪蓋選壓廠 (壓遞餘餘衊築夢繭鑰繭 ) 更多	积极	2021-11-05
NCT04082936 (ASCO2020)	临床1期	淋巴瘤	-	IGM-2323	糧醖顧願蓋鹹積糧鏇顧(窪獵鹽鹹襯糧獵選繭齋) = 鹽壓壓選觸築鹽餘簾膚遞膚鏇遞餘艱衊鏇鬱獵 (鹽壓網顧糧遞顧網範糧 )	-	2020-05-25